KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Rad Laboratories (BIO) Change in Receivables (2016 - 2025)

Bio-Rad Laboratories (BIO) has disclosed Change in Receivables for 17 consecutive years, with $640.0 million as the latest value for Q1 2025.

  • On a quarterly basis, Change in Receivables changed N/A to $640.0 million in Q1 2025 year-over-year; TTM through Mar 2025 was $2.6 billion, a N/A change, with the full-year FY2025 number at $2.7 billion, changed N/A from a year prior.
  • Change in Receivables was $640.0 million for Q1 2025 at Bio-Rad Laboratories, down from $655.5 million in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $728.0 million in Q1 2021 to a low of $640.0 million in Q1 2025.
  • A 5-year average of $678.2 million and a median of $677.1 million in 2023 define the central range for Change in Receivables.
  • Peak YoY movement for Change in Receivables: increased 27.95% in 2021, then fell 5.68% in 2023.
  • Bio-Rad Laboratories' Change in Receivables stood at $728.0 million in 2021, then dropped by 1.45% to $717.4 million in 2022, then fell by 5.68% to $676.7 million in 2023, then decreased by 3.13% to $655.5 million in 2024, then fell by 2.37% to $640.0 million in 2025.
  • Per Business Quant, the three most recent readings for BIO's Change in Receivables are $640.0 million (Q1 2025), $655.5 million (Q3 2024), and $676.7 million (Q4 2023).